GEO series
RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistance
GSE324062
Homo sapiens (human)
Single-cell RNA-seq
61 samples
Submitted 2026/04/01
Platform GPL34284
At a glance
Single-cell RNA-seq · human · 61 samples
- What it is
- Single-cell RNA-seqGene activity measured in thousands of individual cells, so cell types can be told apart. Read from the summary: GEO's own type field only says 'expression profiling by sequencing', so confirm it in the paper.
- Organism
- Homo sapiens (human)
- Topic
- Acute myeloid leukemiaThis series is part of our curated briefing on it.
- Samples
- 61 samples: 54 distinct titles, 5 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Summary (written by the submitters)
Despite efficacy of FLT3 and BCL2 inhibition in acute myeloid leukemia (AML), relapse limits survival. Mutation status and AML monocytic differentiation are implicated in resistance. On-treatment tumor evolution may select for genetically distinct clones or shifts in differentiation not resolvable by bulk sequencing.
Read the full summary ↓
We performed multiomic single cell (SC) DNA/protein and RNA/protein profiling of patients treated on a clinical trial of the BCL2 inhibitor venetoclax and the FLT3 inhibitor gilteritinib (Ven/Git) to characterize immunophenotypic, transcriptional, and genetic clonal evolution on therapy. We found that while Ven/Gilt effectively eliminated FLT3 mutant clones, it selected for RAS mutations, RAS pathway activation and RAS-associated monocytic differentiation. In an in vitro model of monocytic differentiation associated with heightened RAS pathway activation, we demonstrated that MEK inhibition re-sensitized to Ven/Gilt. These data indicate RAS signaling is central to FLT3 and BCL2 inhibitor resistance, is tightly coupled to monocytic differentiation and can be overcome by RAS pathway inhibition.
This dataset
Download · which file do I need?
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
1 · Just have a look
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
2 · Re-analyse it
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE324062_RAW.tar (it can run to tens of gigabytes).
3 · Start from the raw reads
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Single-cell studies usually ship their counts as 10x files (matrix.mtx, barcodes.tsv, features.tsv), an .h5 file, or an .rds / .h5ad object that Seurat or Scanpy can open. Look for those among the supplementary files.
Also filed as BioProject PRJNA1433374 and SRA study SRP681667. Searching any of these in the dataset finder brings you back here.
Study design
54 distinct titles, 5 of them repeated
Primary human samples, DNA; Patient 1 EOC ×3
Primary human samples, DNA; Patient 4 EOC ×3
Primary human samples, DNA; Patient 2 EOC ×2
Primary human samples, DNA; Patient 7 EOC ×2
Primary human samples, DNA; Patient 5 EOC ×2
How we read this: Read from 61 sample titles: 54 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
Samples in this study
- GSM9567603 Primary human samples, DNA; Patients 2 pre-treatment and 7 pre-treatment
- GSM9567604 Primary human samples, cell surface proteins for immunophenotype; Patients 2 pre-treatment and 7 pre-tretment
- GSM9567605 Prrimary human samples, cell surface proteins for multiplexing; Patients 2 pre-treatment and 7 pre-treatment
- GSM9567606 Primary human samples, DNA; Patient 2 end of cycle (EOC) 1
- GSM9567607 Primary human samples, DNA; Patient 2 EOC 4
- GSM9567608 Primary human samples, DNA; Patient 2 EOC 7
- GSM9567609 Primary human samples, DNA; Patient 2 EOC 14, Patient 1 EOC 14, Patient 12 EOC1
- GSM9567610 Primary human samples, cell surface proteins for immunophenotype; Patient 2 EOC 14, Patient 1 EOC 14, Patient 12 EOC1
- GSM9567611 Primary human samples, cell surface proteins for multiplexing; Patient 2 EOC 14, Patient 1 EOC 14, Patient 12 EOC1
- GSM9567612 Primary human samples, DNA; patient 1 pre-treatment
- GSM9567613 Primary human samples, cell surface proteins for immunophenotype; patient 1 pre-treatment
- GSM9567614 Primary human samples, cell surface proteins for multiplexing; patient 1 pre-treatment
- GSM9567615 Primary human samples, DNA; Patient 1 EOC1
- GSM9567616 Primary human samples, DNA; Patient 1 EOC4
- GSM9567617 Primary human samples, DNA; Patient 1 EOC9
- GSM9567618 Primary human samples, DNA; Patient 11 pre-treatment and patient 11 EOC1
- GSM9567619 Primary human samples, cell surface proteins for immunophenotype; Patient 11 pre-treatment and patient 11 EOC1
- GSM9567620 Primary human samples, cell surface proteins for multiplexing; Patient 11 pre-treatment and patient 11 EOC1
- GSM9567621 Primary human samples, DNA; Patient 7 EOC1
- GSM9567622 Primary human samples, DNA; Patient 7 EOC3
- GSM9567623 Primary human samples, DNA; Patient 3 pre-treatment, Patient 8 pre-treatment, Patient 9 pre-treatment
- GSM9567624 Primary human samples, cell surface proteins for immunophenotype; Patient 3, 8, 9 pre-treatment
- GSM9567625 Primary human samples, cell surface proteins for multiplexing; Patient 3, 8, 9 pre-treatment
- GSM9567626 Primary human samples, DNA; Patient 3 EOC4, Patient 3 EOC7
- GSM9567627 Primary human samples,cell surface proteins for immunophenotype; Patient 3 EOC4, Patient 3 EOC7
- GSM9567628 Primary human samples,cell surface proteins for multiplexing; Patient 3 EOC4, Patient 3 EOC7
- GSM9567629 Primary human samples, DNA; Patient 4 pre-treatment, Patient 5 pre-treatment, Patient 12 pre-treatment
- GSM9567630 Primary human samples, cell surface proteins for immunophenotype; Patient 4, 5, 12 pre-treatment
- GSM9567631 Primary human samples, cell surface proteins for multiplexing; Patient 4, 5, 12 pre-treatment
- GSM9567632 Primary human samples, DNA; Patient 4 EOC1
- GSM9567633 Primary human samples, DNA; Patient 4 EOC4
- GSM9567634 Primary human samples, DNA; Patient 4 EOC6
- GSM9567635 Primary human samples, cell surface proteins for immunophenotype; Patient 4 EOC6
- GSM9567636 Primary human samples, cell surface proteins for multiplexing; Patient 4 EOC6
- GSM9567637 Primary human samples, DNA; Patient 5 EOC1
- GSM9567638 Primary human samples, DNA; Patient 5 EOC4
- GSM9567639 Primary human samples, DNA; Patient 6 pre-treatment
- GSM9567640 Primary human samples, cell surface proteins for immunophenotype; Patient 6 pre-treatment
- GSM9567641 Primary human samples, DNA; Patient 6 EOC1
- GSM9567642 Primary human samples, DNA; Patient 8 EOC1
+ 21 more — browse all 61 samples with per-sample file links →
More Acute myeloid leukemia datasets
- GSE303795 Halofuginone exerts broad-spectrum cytotoxic effects by regulating p-eIF2α-S100A8/A9-calcium signaling, inhibiting global protein synthesis, and reversing the resistance of idarubicin in acute myeloid leukemia 6 samples same disease briefing · shares resistance
- GSE137851 The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia 387 samples same disease briefing
- GSE270185 Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia 249 samples same disease briefing
- GSE137574 Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells 24 samples same disease briefing
- GSE129437 Genome-wde mapping of BRD9 binding sites and gene expression changes upon BRD9 knockdown 6 samples same disease briefing
- GSE122515 Bonn Dataset 3 of meta-analysis on AML classification, RNAseq dataset 0 samples same disease briefing
- GSE338135 NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib 75 samples shares flt3, ras, monocytic
- GSE211434 Diverse immune suppressing cancer communications with myeloid cells prevent T cell activation and recruitment and provide resistance to cell cycle inhibitor therapy 81 samples shares activation, resistance, inhibitor
Share this dataset
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.